| NCT ID | NCT04120688 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Turku University Hospital |
| Condition | Tooth Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2020-03-09 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2020-03-09 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to clarify the usefulness of 3D-printed replicas in association with autotransplantation of teeth in children and young adults.
Eligibility Criteria
Inclusion Criteria: * Need for tooth transplantation * Open apex tooth available for transplantation Exclusion Criteria: * Facial syndrome * Chronic facial pain * Allergy to replica material
Contact & Investigator
Hanna Thorén, MD
PRINCIPAL INVESTIGATOR
University of Turku
Frequently Asked Questions
Who can join the NCT04120688 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, up to 23 Years, studying Tooth Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04120688 currently recruiting?
Yes, NCT04120688 is actively recruiting participants. Contact the research team at hanna.thoren@utu.fi for enrollment information.
Where is the NCT04120688 trial being conducted?
This trial is being conducted at Turku, Finland.
Who is sponsoring the NCT04120688 clinical trial?
NCT04120688 is sponsored by Turku University Hospital. The principal investigator is Hanna Thorén, MD at University of Turku. The trial plans to enroll 120 participants.